Corporate and Regional Press Releases

Please find below a list of our press releases.

20 Sep 2018

BTG announces global launch of the ICEfx cryoablation system

September 20, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, today announced the global launch of the ICEfx Cryoablation System. ICEfx, an evolution of the existing Visual ICE system, offers predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation. This compact and powerful console is designed for interventional radiologists who want to offer their patients state-of-the-art, minimally invasive treatment options.

7 Sep 2018

BTG plc acquires Novate Medical Ltd.

BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.

11 Jun 2018

ELEVATE study aims to improve selection criteria and outcomes for patients with severe emphysema treated with the PneumRx Endobronchial Coil System

BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.

4 Apr 2018

SIO and BTG Announce Recipients of Immuno-Oncology/Interventional Oncology Grant Program

The Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, and BTG plc (LSE: BTG), a global healthcare company focused on Interventional Medicine, announce their 2018 Interventional Oncology/Immuno-Oncology research grant recipients.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

11 Dec 2017

Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres

5 Oct 2017

BTG plc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.